# US 2015/0104813 A1 · Materials and methods for evaluating and treating neuromyelitis optica (nmo)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104813 A1
- Document ID: US20150104813A1
- Status: Published application
- Kind: A1
- Application number: 14/470,667
- Filed: 2014-08-27
- Published: 2015-04-16
- Earliest claimed: 2008-10-10
- Assignees: Mayo Foundation for Medical Education and Research
- Applicants: Mayo Foundation for Medical Education and Research
- Inventors: Vanda A. Lennon; Shannon Hinson; Sean J. Pittock
- Web page: https://patentgrep.com/patent/US20150104813A1

## CPC

- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- G01N 2800/285: Demyelinating diseases; Multipel sclerosis
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides prognostic methods for evaluating the severity of NMO and NMO-associated diseases as well as methods of treating NMO and NMO-associated diseases.

## Claims

### Claim at position 1

1-12. (canceled)

### Claim 13

A method comprising:
administering an effective amount of an antibody to an individual having NMO, wherein the antibody is an anti-NMO antigen antibody having specific binding affinity for a NMO antigenic polypeptide.

### Claim 14 (depends on 13)

The method of claim 13, wherein the antibody comprises a label.

### Claim 15 (depends on 14)

The method of claim 14, wherein the label is an imaging agent.

### Claim 16 (depends on 15)

The method of claim 15, wherein the imaging agent is selected from the group consisting of 32P, 99Tc, 111In and 131I.

### Claim 17 (depends on 14)

The method of claim 14, wherein the effective amount is an amount of from about 0.1 mCi to about 50.0 mCi.

### Claim 18 (depends on 13)

The method of claim 13, wherein the effective amount is an amount of from about 0.01 mg to about 100 mg.

### Claim 19 (depends on 13)

The method of claim 13, wherein the antibody is administered to the individual parenterally.

### Claim 20 (depends on 13)

The method of claim 13, wherein the antibody is administered to the individual intravenously.
